Phase III Trial of 4SCAR19 CAR-T Cells for Treating Relapsed or Refractory B Cell Malignancies

What this Trial Is About

Researchers are evaluating the safety and effectiveness of a new fourth-generation gene-modified T cell therapy called 4SCAR19, which targets CD19-positive B cell malignancies. This phase III trial involves multiple clinical centers and focuses on patients with relapsed or refractory B cell cancers that have not responded to standard treatments. The study also aims to develop a standardized method for producing these modified cells using lentiviral vectors. Participants will undergo a process where their peripheral blood mononuclear cells are collected through apheresis, and their T cells are activated and genetically modified with the 4SCAR19 gene. Before receiving the modified T cells, participants will get a conditioning chemotherapy regimen of cyclophosphamide and fludarabine to prepare their immune system. The modified 4SCAR19 T cells will then be infused, and participants will be closely monitored for treatment responses and safety. Throughout the study, participants will have regular assessments to track the presence of CAR T cells and observe clinical responses. Safety will be evaluated over 24 weeks using standard criteria for adverse events, while anti-tumor activity will be followed for up to one year. The trial requires ongoing monitoring after treatment to understand the therapys effects and safety profile over time.

A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies